Clinical Efficacy of Escitalopram Oxalate and Vortioxetine Hydrobromide in Treatment of First-episode Depression
Objective To investigate the clinical efficacy and adverse reactions of escitalopram oxalate and vortioxetine hydrobromide in the treatment of first-episode depression.Methods A total of 70 pa-tients with first-episode depression were divided into escitalopram oxalate group and vortioxetine hydrobro-mide group according to random number table method,with 35 cases in each group.Escitalopram group was given escitalopram orally,and vortioxetine hydrobromide group was given vortioxetine hydrobromide orally.The Hamilton Depression Scale-24(HAMD-24),the Quick Inventory of Depressive Symptoma-tology 16-Item Self-Report(QIDS-SR16)and the Montgomery Depression Rating Scale(MADRS)were used to evaluate the depression of patients before treatment and 2,4 and 8 weeks after treatment.Results There was no significant difference in HAMD-24,QIDS-SR16 and MADRS scores between the two groups before treatment(P＞0.05).The scores of HAMD-24,QIDS-SR16 and MADRS in the two groups at 2,4 and 8 weeks after treatment were lower than those before treatment(P＜0.05),and the scores decreased with the time after treatment(P＜0.05).There was no significant difference between the two groups at the same time point after treatment(P＞0.05).The incidence of adverse reactions such as nausea,headache and somnolence in escitalopram group was higher than that in vortioxetine hydrobro-mide group,and the difference was statistically significant(P＜0.05).Conclusion Both escitalopram oxalate and vortioxetine hydrobromide are effective in the treatment of first-episode depression,but vor-tioxetine hydrobromide has fewer adverse reactions and higher safety.
万方数据
维普
